Citigroup Inc Bioventus Inc. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Bioventus Inc. stock. As of the latest transaction made, Citigroup Inc holds 27,445 shares of BVS stock, worth $292,838. This represents 0.0% of its overall portfolio holdings.

Number of Shares

27,445

Previous 8,522 222.05%

Holding current value

$292,838

Previous $49,000 567.35%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$5.73 - $11.95 $108,428 - $226,129	18,923 Added 222.05%	27,445 $327,000
Q2 2024 Aug 12, 2024	SELL	$3.96 - $6.93 $480,494 - $840,865	-121,337 Reduced 93.44%	8,522 $49,000
Q1 2024 May 10, 2024	BUY	$4.33 - $5.75 $23,104 - $30,682	5,336 Added 4.29%	129,859 $675,000
Q4 2023 Feb 09, 2024	BUY	$2.89 - $5.34 $208,051 - $384,426	71,990 Added 137.04%	124,523 $656,000
Q3 2023 Nov 09, 2023	BUY	$2.8 - $4.94 $146,008 - $257,601	52,146 Added 13474.42%	52,533 $173,000
Q2 2023 Aug 10, 2023	BUY	$0.93 - $3.64 $293 - $1,150	316 Added 445.07%	387 $1,000
Q1 2023 May 11, 2023	SELL	$1.07 - $2.95 $974 - $2,687	-911 Reduced 92.77%	71 $0
Q4 2022 Feb 09, 2023	SELL	$1.81 - $8.14 $30,469 - $137,028	-16,834 Reduced 94.49%	982 $2,000
Q3 2022 Nov 10, 2022	SELL	$6.54 - $9.08 $8,704 - $12,085	-1,331 Reduced 6.95%	17,816 $125,000
Q2 2022 Aug 10, 2022	BUY	$6.82 - $13.82 $11,948 - $24,212	1,752 Added 10.07%	19,147 $131,000
Q1 2022 May 12, 2022	SELL	$11.65 - $15.28 $9,308 - $12,208	-799 Reduced 4.39%	17,395 $245,000
Q4 2021 Feb 10, 2022	SELL	$12.37 - $16.77 $16,464 - $22,320	-1,331 Reduced 6.82%	18,194 $264,000
Q3 2021 Nov 10, 2021	BUY	$13.7 - $17.25 $267,492 - $336,806	19,525 New	19,525 $276,000

Others Institutions Holding BVS

# of Institutions

141

Shares Held

45.8M

Call Options Held

179K

Put Options Held

124K

View Full List

About Bioventus Inc.

Ticker BVS
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 61,664,200
Market Cap $658M
Description
Bioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral ner...

More about BVS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account